Genome Engineering Market

1. According to Transparency Market Research’s latest report on the global genome engineering market for the historical period 2017–2018 and forecast period 2019–2027, increased funding in genomic research, technological developments, rising demand for synthetic genes, and investment by pharmaceutical companies for new product development are projected to drive the global genome engineering market during the forecast period According to the report, the global genome engineering market was valued at US$ 3,685.4 Mn in 2018 and is anticipated to expand at a CAGR of 10.9% from 2019 to 2027   Increased Funding In Genomic Research: Key Drivers Synthetic biology received funding of US$ 430 Mn in the U.S. from 2005 to 2010, which was much higher than US$ 160 Mn in Europe during the same period. The U.K. contributed around US$ 30 Mn. About 4% and 2% funding in the U.S. and Europe, respectively, was spent to explore ethical, social, and legal implications (ELSI) of synthetic biology. Government initiatives are on par with private investments. More than $700 million was spent on synthetic biology research, by Department of Energy (DOE). While NIH awarded a grant of $40 million for the same. Universities across the globe have provided significant funding for research in synthetic biology. For instance, in 2008, three Dutch universities — Delft University of Technology (Department of Bionanoscience), University of Groningen (Centre for Synthetic Biology), and the Eindhoven University of Technology (Institute for Complex Molecular Systems) — declared they would invest around USD $90 million in synthetic biology research for a period of 5 years to 10 years. Application of genome engineering in animals has increased significantly in the past few years. Usage of this technology brings with it ethical issues that relate to animal welfare.     Request https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4671 Sample: Investment by Pharmaceutical Companies for Developing New Treatments Boost Market Growth Pharmaceutical firms have realized the new trends of treating genetic diseases by gene editing technologies. They are collaborating with gene editing companies to develop treatment option.  In December 2015, Bayer and CRISPR Therapeutics AG formed a joint agreement, to develop new technology to cure blindness, blood disorders, and congenital heart disease. Bayer would be utilizing the CRISPR-Cas9 gene editing technology and would use its protein-engineering technology for the same. Bayer will contribute a minimum of USD 300 million in R&D investments in this joint venture. In January 2015, Novartis formed a collaboration with Intellia and Caribou, which would help Novartis to use CRISPR genome editing technology to engineer chimeric antigen receptor (CAR) T cells and hematopoietic stem cells and also to discover and develop  

2. other medicine. This collaboration received an undisclosed amount from Novartis and USD $15 million from both Intellia and Caribou. Enquiry https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=467 1 Before Buying: Stringent Regulatory Framework to Hamper Market There are various regulatory frameworks for genetically modifying plant genome. Process based regulatory frameworks consider the techniques used to create new crop plant varieties. The regulation is triggered when the plant is developed by using recombinant DNA technology. The definitions and guidelines for regulation was decided by the organizations such as the United Nations Food and Agricultural Organization and treaties such as the Cartagena protocol. The regulation is followed in Europe, Argentina, Brazil, and several other regions. The product based regulatory framework that prevails in the U.S. and Canada primarily focuses on the inherent risk of the final product, rather than the technology used to make it.  Request https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4671 Brochure: Global Genome engineering Market: Competitive Landscape This report profiles major players in the global genome engineering market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments  The major players operating in the global genome engineering market are  oApplied Stem Cell, Inc. oGenScript oHorizon Discovery Group plc oIntegrated DNA Technologies, Inc. oLonza Group Ltd. oNew England Biolabs oOriGene Technologies, Inc. oSangamo BioSciences, Inc. oSigma-Aldrich Co. LLC. oThermo Fisher Scientific, Inc.,

3. oTransposagen Biopharmaceuticals, Inc. About Us Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals. Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real- time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories. TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision. Contact Rohit Bhisey Transparency Market Research Inc. CORPORATE HEADQUARTER DOWNTOWN, 1000 N. West Street, Suite 1200, Wilmington, Delaware 19801 USA Tel: +1-518-618-1030 USA - Canada Toll Free: 866-552-3453 Email: sales@transparencymarketresearch.com Website: https://www.transparencymarketresearch.com/